NCT01420744已完成2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group, Adaptive Group-sequential Phase II Study, to Determine the Efficacy and Safety of BT086 as an Adjunctive Treatment in Severe Community Acquired Pneumonia (sCAP)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biotest
- 入组人数
- 160
- 试验地点
- 36
- 主要终点
- Ventilator Free Days (VFDs)
研究概览
简要总结
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe Community-Acquired Pneumonia (sCAP).
详细描述
Severe Community-Acquired Pneumonia (sCAP) is usually defined clinically as pneumonia acquired from outside the hospital (CAP) that requires intensive medical care. Mortality of (s)CAP patients admitted to ICU range from 35-58% depending on time and admission of the patient and has not much improved in the last years.
BT086 contains a sufficient number of antibodies against the most frequent pathogens as well as antibodies against lipopolysaccharides and lipid A. Therefore, it can be assumed that administration of BT086 early in the clinical course of a severe infection such as sCAP may provide an effective adjunctive treatment to standard antibiotic therapy for sCAP patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent:
- •given by the patient or
- •a legal/authorised representative of the patient or
- •a waiver for written informed consent due to emergency situation, in compliance with all local legal requirements.
- •Male or female patients aged 18 years or older
- •Patient receiving adequate antibiotic treatment for pneumonia
- •Prior to endotracheal ventilation and therapy, the patient must have at least one of the following two signs of inflammation:
- •Fever/Hypothermia Fever defined as an oral, tympanic, oesophageal or vesical temperature of >38°C, tympanic temperature of >38°C or rectal temperature of >38.5°C, or hypothermia (rectal temperature <35.5°C) (measurement with temperature probe or device) or
- •White blood cell (WBC) count >10,000/mm³ or WBC <4,500/mm³
- •Patient must have at least one of the following signs and symptoms of pneumonia:
- •New or increased cough
- •Production of purulent sputum or change in sputum characteristics
- •Dyspnoea or tachypnoea (respiratory rate >20 breaths/minute)
- •Pleuritic chest pain
- •Auscultatory findings on pulmonary examination of rales and/or crackles and/or evidence of pulmonary consolidation (e.g. dullness on percussion, bronchial breath sounds, or egophony)
- •Radiological (or other imaging technique) evidence of (an) infiltrate(s) consistent with bacterial pneumonia
- •Pneumonia has been acquired outside the hospital. In hospital-admitted patients, pneumonia has been diagnosed a maximum of 72 hours after admission. Patients from nursing homes or similar institutions are eligible.
- •Major sCAP criterion: need for endotracheal ventilation
- •Treatment of patient with BT086 must start within 12 hours but not earlier than 1 hour after start of endotracheal ventilation
排除标准
- •For incapacitated patients: any indication that the patient's presumed will would be against inclusion in the trial
- •Patients with suspected hospital-acquired pneumonia
- •Severe lung diseases interfering with sCAP therapy e.g. patients with cystic fibrosis,
- •Patients receiving Xigris® (drotrecogin alfa, activated Protein C) or medications not approved for sCAP (e.g. Dornase alpha) are excluded from inclusion in the study
- •Patients on dialysis
- •Presence of other severe diseases impairing life expectancy (e.g. patients are not expected to survive 28 days given their pre-existing uncorrectable medical condition).
- •Patients unable to be treated due to obesity
- •Selective, absolute IgA deficiency with known antibodies to IgA
- •Patients with neutrophil count <1,000/mm³ or platelet count <50,000/mm³
- •Pregnant or lactating women. A pregnancy test will be performed in all women aged <65 years and the result must be available at study inclusion.
- •Known relevant intolerance to immunoglobulins, vaccines or other substances of human origin
- •Participation in another interventional clinical trial within 30 days before entering the study or during the study, and/or previous participation in this study (participation in non-interventional trials is allowed).
研究组 & 干预措施
BT086 infusion
Experimental
干预措施: BT086 (Drug)
1% Human Albumin infusion
Placebo Comparator
干预措施: 1% Human Albumin infusion (Drug)
结局指标
主要结局
Ventilator Free Days (VFDs)
时间窗: 28 days
VFDs are defined as the number of days between successful weaning from endotracheal ventilation and day 28 after study enrolment.
次要结局
- 28-day pneumonia-cause mortality(28 days (672 hours from randomization))
- Time (days) to discharge from ICU(28 days)
- Time (days) to discharge from hospital(28 days)
- SOFA: Score Sequential Organ Failure Assessment(28 days)
- Vasopressor-free days(28 days)
- Glasgow Coma Score(28 days)
- 28-day all cause mortality(28 days (672 hours from randomization))
研究者
研究点 (36)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis ExternaAcute Otitis ExternaNCT03196973Salvat493
已完成
3 期
Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric PatientsAcute Otitis MediaNCT01404611Salvat331
已完成
3 期
A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis.Urinary Tract InfectionsPyelonephritisNCT00210886Johnson & Johnson Pharmaceutical Research & Development, L.L.C.1,109
已完成
不适用
Antibiotic Therapy Versus Appendectomy for Acute AppendicitisAppendicitisNCT00135603Assistance Publique - Hôpitaux de Paris243
已完成
3 期
Effectiveness of Antibiotic Prophylaxis for Totally Implantable Venous Access DeviceSolid TumorNCT00867295Istanbul University150